BlackRock Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlackRock Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.18M	Buy	144,713 +179	+0.1%	+$2.53K	﹤0.01%	2164
2016 Q3	$2.2M	Sell	144,534 -54,121	-27%	-$2.19M	﹤0.01%	2080
2016 Q2	$7.71M	Buy	198,655 +31,060	+19%	+$1.12M	0.01%	1124
2016 Q1	$4.66M	Buy	167,595 +11,454	+7%	+$382K	0.01%	1427
2015 Q4	$8.4M	Buy	156,141 +10,502	+7%	+$530K	0.01%	1052
2015 Q3	$5.83M	Buy	145,639 +25,037	+21%	+$817K	0.01%	1271
2015 Q2	$3.85M	Sell	120,602 -5,719	-5%	-$145K	﹤0.01%	1707
2015 Q1	$3.02M	Buy	126,321 +16,931	+15%	+$379K	﹤0.01%	1742
2014 Q4	$1.93M	Sell	109,390 -565	-0.5%	-$8.83K	﹤0.01%	2066
2014 Q3	$1.51M	Buy	109,955 +1,047	+1%	+$15.7K	﹤0.01%	2215
2014 Q2	$1.84M	Buy	+108,908	New	+$1.8M	﹤0.01%	2144

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's ITCI Position: Q4 2016 in Review

BlackRock Investment Management increased its Intra-Cellular Therapies Inc. (ITCI) stake by 0.12% in Q4 2016, buying an estimated $2.53K and bringing the position to 144,713 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2164.

BlackRock Investment Management first reported a position in ITCI in Q2 2014 and has held it in 11 quarters since. The position peaked at $8.4M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

BlackRock Investment Management held 144,713 shares of Intra-Cellular Therapies Inc. worth $2.18M as of Q4 2016.
BlackRock Investment Management bought 179 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $2.53K.
Intra-Cellular Therapies Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2164 holding.
BlackRock Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Intra-Cellular Therapies Inc. position peaked at $8.4M in Q4 2015.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.